Low molecular weight heparins: the optimal treatment for venous thromboembolism

References

• Hull RD, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676–81
   PubMed Web of Science ®Google Scholar
• Hirsh HJ. Heparin. N Engl J Med 1991;324:1565–74
   PubMed Web of Science ®Google Scholar
• Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, et al. Prevention of venous thromboembolism. Chest 2001;119(1 Suppl):132S–175S
   Google Scholar
• Harenberg J, Schmitz-Huebner U, Breddin KH, Hass S, Heinrich F, Heinrichs C, et al. Treatment of deep vein thrombosis with low-molecular-weight heparins: a consensus statement of the Gesellschaft fur Thrombose-und Hamostaseforschung (GTH). Semin Thromb Hemost 1997;23:91–6
   PubMed Web of Science ®Google Scholar
• Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601–7
   PubMed Web of Science ®Google Scholar
• Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996;100:269–77
   Google Scholar
• Hyers TM, Angelli G, Hull RD, Weg JG, Morris TA, Samama M, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998;114\(Suppl 5):561S–78S
   Google Scholar
• Fareed J, Haas S, Sasahar A. Past, present and future considerations on low molecular weight heparin differentiation: An epilogue. Semin Thromb Hemost 1999;25(Suppl 3):145–7
   Google Scholar
• Mousa SA. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: Implications for management of vascular disorders. Semin Thromb Hemost 2000;26(Suppl 1):39–46
   PubMed Web of Science ®Google Scholar
• Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119\(Suppl 1):176S–93S
   Google Scholar
• Pabinger-Fasching I. Monitoring blood coagulation. Wien Med Wochenschr 1999;149:70–1
   PubMedGoogle Scholar
• Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996 ;334:682–7. Erratum in: N Engl J Med 1997;337: 1251
   Google Scholar
• Caiola E. Heparin-induced thrombocytopenia: how to manage it, how to avoid it. Cleve Clin J Med 2000;67:621–4
   PubMed Web of Science ®Google Scholar
• Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications for coumarin. Thromb Haemost 1994;71:7–11
   Google Scholar
• Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the effects of heparin and low molecular weight heparin on cancellous bone in rats. Blood 1997;89:3236–42
   PubMed Web of Science ®Google Scholar
• Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998;114 (Suppl 5):511S–23S
   Google Scholar
• Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999;14:303–12
   PubMed Web of Science ®Google Scholar
• Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423–8
   Google Scholar
• Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078–83
   PubMed Web of Science ®Google Scholar
• Meissner MH, Manzo RA, Bergelin RO, Strandness DE Jr. Deep venous insufficiency: the relationship between lysis and subsequent reflux. J Vasc Surg 1993;18:596–605
   Google Scholar
• Liapis CD, Daskalopoulos ME, Daskalopoulou SE. Low molecular weight heparins in the long-term treatment of venous thromboembolism. J Cardiovasc Surg (Torino) 2002;43:495–500
   PubMed Web of Science ®Google Scholar
• Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N Engl J Med 1997;337:663–9
   Google Scholar
• Harenberg J, Leber G, Dempfle CE, Heene DL, Zimmermann R, Kubler W. Long term anticoagulation with low molecular weight heparin in outpatients with side effects on oral anticoagulants. Nouv Rev Fr Hematol 1989;31:363–9
   PubMedGoogle Scholar
• Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al. Low molecular weight heparin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191–7
   PubMed Web of Science ®Google Scholar
• Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using low-molecular-weight heparin. Semin Thromb Hemost 1997;23:167–72
   Google Scholar
• Harenberg J, Leber G, Augustin J, Raedsch R, Schwarz F, Stiehl A, et al. Ambulatory long-term prevention of thromboembolism with low-molecular-weight heparin. Klin Wochenschr 1987;65:331–7
   PubMedGoogle Scholar
• Vitoux JF, Fiessinger JN, Roncato M, Pernes JM, Brenot P, Aiach M. Long-term treatment of acute deep venous thrombosis with low-molecular-weight heparin derivative. JAMA 1988;259:1180–1
   PubMed Web of Science ®Google Scholar
• Mazokopakis EE, Vrentzos GE, Ganotakis ES. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients. Curr Med Res Opin 2003;19: 565–6
   Google Scholar
• Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomised trial. World J Surg 1996;20:521–7
   Google Scholar
• Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26–31
   PubMed Web of Science ®Google Scholar
• Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agundez I, et al. Venographic comparison of sub-cutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999;30:283–92
   Google Scholar
• Veiga F, Escriba A, Maluenda MP, Lopez Rubio M, Margalet I, Lezana A, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84:559–64
   Google Scholar
• Lopez-Beret P, Orgaz A, Fontcuberta J, Doblas M, Martinez A, Lozano G, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001;33:77–90
   Google Scholar
• Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomised controlled study. Arch Intern Med 2002;162:1729–35
   Google Scholar
• Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53
   PubMed Web of Science ®Google Scholar
• Monreal M. Long-term treatment of venous thromboembolism with low-molecular-weight heparin. Curr Opin Pulm Med 2000;6:326–9
   PubMedGoogle Scholar
• van der Heijden JF, Hutten BA, Boller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Review). Cochrane Database Syst Rev 2000;(4):CD002001
   Google Scholar
• van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002;(1):CD002001
   Google Scholar
• Daskalopoulos M, Daskalopoulou S, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2004; in press
   Google Scholar
• Makatsaria AD, Bitsadze VO, Dolgushina NV. Use of the low-molecular-weight heparin nadroparin during pregnancy. A review. Curr Med Res Opin 2003;19:4–12
   PubMedGoogle Scholar
• Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119:S344–70
   PubMed Web of Science ®Google Scholar
• Liebowitz RS. Deep venous thrombosis: Thinking inside out. Arch Intern Med 1998;158:1964
   PubMed Web of Science ®Google Scholar